Clough Capital Partners L P Makes New Investment in Denali Therapeutics Inc. $DNLI

Clough Capital Partners L P bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 51,830 shares of the company’s stock, valued at approximately $856,000.

A number of other institutional investors have also recently bought and sold shares of the business. State of Wyoming grew its holdings in Denali Therapeutics by 24.7% during the 4th quarter. State of Wyoming now owns 2,686 shares of the company’s stock worth $44,000 after acquiring an additional 532 shares during the period. Intrust Bank NA grew its holdings in Denali Therapeutics by 5.6% during the 4th quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock worth $184,000 after acquiring an additional 589 shares during the period. ADAR1 Capital Management LLC grew its holdings in Denali Therapeutics by 1.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock worth $860,000 after acquiring an additional 600 shares during the period. Pier 88 Investment Partners LLC grew its holdings in Denali Therapeutics by 1.1% during the 4th quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after acquiring an additional 760 shares during the period. Finally, Tudor Investment Corp ET AL grew its holdings in Denali Therapeutics by 1.7% during the 3rd quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after acquiring an additional 920 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. UBS Group reissued a “buy” rating on shares of Denali Therapeutics in a research report on Tuesday. Leerink Partners decreased their price target on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Robert W. Baird boosted their price target on shares of Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Morgan Stanley decreased their price target on shares of Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Friday, May 22nd. Finally, HC Wainwright boosted their price target on shares of Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and an average target price of $34.25.

Denali Therapeutics Price Performance

Shares of DNLI stock opened at $23.49 on Thursday. Denali Therapeutics Inc. has a 12-month low of $12.58 and a 12-month high of $24.21. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of -8.16 and a beta of 1.03. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $19.94 and a 200-day moving average of $19.52.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same quarter last year, the business posted ($0.78) earnings per share. On average, equities research analysts forecast that Denali Therapeutics Inc. will post -2.77 earnings per share for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.